Treatments used today, potential future treatments that have reached studies in people with congenital hyperinsulinism, and longer-term research that may shape future care.
Overview
The immediate goal of treating congenital hyperinsulinism (CHI) is to keep glucose in a safe range to protect the brain. How that is accomplished varies with the cause and form of CHI, whether medicines such as diazoxide work, and the needs of the individual child or adult.
This page introduces the medicines, feeding support, monitoring, and surgery used today. It also looks at potential future treatments that have reached studies in people with CHI, and at earlier-stage research that might contribute to future care. The sections explain what each approach is intended to do, who it might help, and how far the evidence has progressed.
The page is organized into five sections: care used today, how CHI may change over time, and three stages of potential future research.
01 · Current treatments used todayMedicines, feeding support, monitoring, surgery, and plans for responding to occasional low-glucose episodes.
Establishing medicines, feeding, glucose checks, and equipment routines after diagnosis can take time and energy. As families become familiar with them, many tasks become more manageable, although each family’s experience is different.
All CHI forms during initial stabilization
Stabilizing glucose in hospital
What the hospital team does: When CHI is first suspected, clinicians in the hospital work to bring the child’s glucose into a safe range while they investigate the cause. If an infant’s glucose remains low despite feeding, the medical team may set up an intravenous (IV) line to deliver dextrose, a form of glucose, directly into the bloodstream. Glucagon may also be given to tell the liver to release stored glucose and make additional glucose.
What parents may see: The amount of dextrose may be adjusted frequently as the team learns how much support the child needs. Some infants need a central intravenous line so that more concentrated dextrose can be given without supplying excessive fluid. Glucagon may be given through a separate infusion pump.
What happens next: These supports usually act as a bridge while the team confirms hyperinsulinism, begins genetic or other testing, and determines whether medicines such as diazoxide can maintain safe glucose. Needing substantial support at first does not by itself determine what the child’s long-term course will be.
Why it is usually tried first: Diazoxide is generally the first medicine used to try to control persistent CHI after glucose has been stabilized. It keeps A beta-cell channel that links nutrient sensing to insulin release. It contains SUR1, encoded by ABCC8, and Kir6.2, encoded by KCNJ11. open, helping responsive beta cells stop releasing insulin when glucose is low.
Why the response matters: If diazoxide works well, a child may be able to leave the hospital with oral medicine, glucose monitoring, and an individualized feeding plan rather than needing intravenous glucose or second-line treatment. Some ABCC8- or KCNJ11-related CHI does not respond because the affected KATP channels cannot open adequately.
How the team evaluates it: The team watches whether the child can maintain safe glucose as intravenous support is reduced and during an age-appropriate period without feeding. If diazoxide does not work, that result helps guide rapid genetic testing, specialized imaging, and consideration of other treatments.
What care can involve: Diazoxide is commonly given with a diuretic in infants to limit fluid retention. Monitoring may include an echocardiogram, blood tests, and attention to swelling, breathing changes, feeding, and excess hair growth.
Safety details and sources
Clinicians watch especially closely for pulmonary hypertension in premature infants and in children with respiratory illness or structural heart disease, because these conditions can increase the risk during diazoxide treatment. For infants, care commonly includes a thiazide diuretic to limit fluid retention and echocardiographic screening around the start of treatment; the exact timing depends on the center and the child’s risk factors. Study percentages describe groups of patients, and the care team considers each child’s age and underlying health when planning monitoring.
Diazoxide response is judged by whether treatment produces safe glucose control. Nonresponse does not prove that every beta cell lacks all KATP-channel activity, and it does not rule out a later decrease in CHI severity. Researchers are still studying why some KATP-channel CHI enters remission.
How they work: Octreotide is a A medicine that imitates some actions of the natural hormone somatostatin and can reduce insulin secretion.. It is an established second-line treatment when diazoxide does not work or causes unacceptable side effects. By reducing insulin release, it can improve glucose stability, reduce the amount of added glucose or continuous feeding needed, and sometimes allow longer intervals between feeds. Short-acting octreotide is usually given several times a day or continuously through a pump. This allows the clinical team to adjust the dose and assess how the child responds. Once glucose is more stable and an effective dose is understood, some children use a long-acting somatostatin analogue, such as octreotide LAR or lanreotide, usually given about once a month. Long-acting treatment can reduce the burden of daily injections or pump care, but its dose cannot be adjusted as quickly.
What care can involve: Injection or pump care, glucose monitoring, and follow-up of growth, gastrointestinal symptoms, liver and thyroid tests, and the gallbladder.
Benefits, safety details, and sources
Octreotide is an important option for many children with diazoxide-unresponsive CHI, and studies have found that it is effective and well tolerated in many patients. Its effect can lessen over time, so teams reassess glucose patterns, dosing, and feeding support. In premature or medically unstable newborns, specialists use it especially carefully because NEC is a serious condition in which part of a newborn’s intestine becomes inflamed and injured. Prematurity, serious illness, and unstable circulation can increase the risk. It is uncommon, but it is one reason specialists monitor high-risk newborns closely when using octreotide. has been reported. Specialists weigh this risk against octreotide’s important ability to improve glucose control when diazoxide has not worked.
These medicines are generally used off label for CHI in the United States. In a small selected cohort, gallbladder sludge or stones appeared within months in some children, which is why periodic monitoring matters.
How it fits into care: After the immediate low-glucose crisis has been treated, the team begins testing feeding approaches that may help keep glucose safe outside the hospital. Finding a workable plan can take time, and feeding support is often adjusted alongside medicines and further testing.
What it does: Scheduled meals and snacks, formula or breast milk, added glucose polymers, and continuous feeds through an NG or G-tube can help prevent fasting hypoglycemia. Some plans use formula with added carbohydrate rather than a glucose-only solution.
What care can involve: A CHI dietitian can adjust the carbohydrate concentration, formula composition, and feed volume to support glucose stability while limiting overfeeding and feeding intolerance. Families may also manage tube and pump care, supplies, alarms, school coordination, and overnight routines.
A A small area of the pancreas where beta cells release too much insulin. Outside that area, the pancreas generally regulates insulin normally. can usually be removed while preserving most of the pancreas, and that usually cures the CHI.
For CHI in which abnormal insulin regulation is spread broadly throughout the pancreas rather than limited to one removable area, and intensive treatment has not kept glucose adequately safe., a 2023 international consensus guideline conditionally suggests surgery when hypoglycemia cannot be controlled adequately despite intensive treatment with medicines and feeding support. If surgery is chosen, the guideline describes removing approximately 90% to 98% of the pancreas, called a near-total pancreatectomy.
Unlike removal of a focal lesion, near-total pancreatectomy does not reliably restore normal glucose regulation. It can eliminate hypoglycemia in some children and often makes it less severe in others, but many children still need treatment for low glucose afterward. Removing so much of the pancreas also creates substantial risks of later diabetes and difficulty producing the pancreatic enzymes needed to digest food.
Expected outcomes, different approaches, and questions to discuss
What surgical studies found: In a CHOP study of 202 children with diffuse CHI who underwent approximately 98% pancreatectomy, 31% had glucose in the normal range after surgery, 20% had high glucose, and 49% still required treatment for hypoglycemia. At another specialist center, 60% of 45 children continued to have hypoglycemia after near-total pancreatectomy, although it was generally less severe and could usually be managed with medicines or feeding. In that study, insulin-dependent diabetes affected 96% by 11 years after surgery, and 49% developed symptoms of pancreatic enzyme insufficiency.
Why some teams continue nonsurgical treatment longer: Some reports use the term subtotal pancreatectomy. In CHI literature, this also means removing most of the pancreas, not a small focal resection. The exact percentage varies among reports, and a subtotal operation can approach a near-total one.
Studies from Spain, Israel, and the UK have followed medically managed children with diffuse or presumed-diffuse KATP-channel CHI, including some severe diffuse cases. In the UK cohort, hypoglycemia resolved in 15 of 21 patients, including 13 of 19 classified as diffuse or presumed diffuse; the authors identified five as having severe diffuse CHI. In the Spanish cohort, 12 of 17 followed patients entered remission, and ten had two ABCC8 variants, a genetic pattern generally associated with diffuse CHI. The Israeli cohort included 11 children genetically classified as diffuse and reported generally good long-term outcomes for the conservatively treated group.
These studies show that prolonged treatment with medicines and feeding support can be a reasonable path for some children with diffuse CHI, including some severe cases.
What remains uncertain: We did not find a study that directly compared near-total pancreatectomy with continued medical and feeding treatment in children whose CHI was similarly severe. The surgical and nonsurgical studies followed different groups whose treatment had already been chosen by their clinical teams. Their percentages therefore cannot tell families which approach would produce the better outcome for a particular child. Specialist teams may also differ in when they conclude that nonsurgical treatment is no longer safe enough.
Questions families can ask:
How certain is the diffuse diagnosis?
Can glucose currently be maintained safely?
Which medicines and feeding approaches have been tried or considered?
With the feeding approaches tried for my child, what tends to happen before low-glucose episodes? For example, do the lows occur after vomiting, during or after several hours of dextrose-only tube feeding, or after a feeding by mouth given soon afterward?
Could the team test whether adjusting the feed’s composition, carbohydrate content, volume, or timing reduces low-glucose episodes?
If overnight lows or vomiting occur during dextrose-only tube feeding, could the team conduct a closely supervised trial using an appropriate formula or another nutritionally complete feed instead, with the carbohydrate and volume adjusted to avoid overfeeding, and evaluate whether glucose stability improves?
If surgery is proposed, is its goal to eliminate hypoglycemia or make it less severe?
What are this center’s rates of persistent hypoglycemia, diabetes, pancreatic enzyme insufficiency, complications, and repeat surgery?
How would the team monitor safety and reassess the child if surgery were postponed?
Before deciding whether to proceed with near-total pancreatectomy for diffuse CHI, families can seek an independent second opinion from another specialist CHI center of their choice, ideally one experienced in evaluating both surgical and nonsurgical approaches.
Congenital Hyperinsulinism International also offers a family-oriented Questions Before Surgery discussion guide.
Before going home: the low-glucose and emergency plan
Why it matters: This is not another treatment. It is the written safety plan for what caregivers should do if glucose falls despite treatment, or if feeding or medicine is interrupted. The plan should reflect the child’s age, usual glucose targets, symptoms, ability to eat or drink safely, medicines, feeding support, and available equipment. Families should review and practice it before discharge and update it whenever care changes.
If the child is awake and can swallow safely: The plan may call for a measured amount of fast-acting carbohydrate, such as glucose gel, juice, or another source approved by the care team, followed by another glucose check after the specified interval. Some individualized plans may use a feeding tube.
If the child cannot swallow safely, is unconscious, or is having a seizure: Nothing should be put in the mouth. Caregivers may be instructed to give prescribed rescue glucagon and seek emergency help according to the written plan.
What families can ask about: For infants and young children, the appropriate rescue-glucagon dose may depend on the child’s weight and the exact product. Families can ask their CHI team to specify the glucose threshold, treatment, recheck timing, glucagon product and dose, and emergency steps in writing, and to train everyone who may need to follow the plan.
Care guidance and sources
International HI guidelines recommend access to emergency rescue glucagon and an individualized emergency-management plan for people with ongoing hypoglycemia. Product instructions differ, so the written plan should identify the exact glucagon product and pediatric dose.
How the two types of glucose checks differ: A blood-glucose meter uses a small drop of blood, usually from a finger or an infant’s heel, to give one glucose reading at that moment. A continuous glucose monitor uses a sensor under the skin to estimate glucose every few minutes and display readings and trends on a phone or receiver.
Why families may consider one: A CGM can help families and clinicians identify recurring patterns, including overnight patterns, and see how medicines, feeding schedules, activity, or interrupted tube feeding may affect glucose. An alarm may prompt a blood-glucose meter check, but it cannot be relied upon to detect every low.
How it fits into care: CGMs can miss hypoglycemia, give false alarms, and lag behind blood glucose when levels are changing quickly. Families should continue blood-glucose meter checks on the individualized schedule provided by their child’s CHI team. The written plan should explain when to confirm a CGM reading with the meter, what to do if the readings disagree, and when treatment should not be delayed. The schedule may include checks before feeds or at set intervals, with additional checks during illness, interrupted feeds, medication changes, symptoms, or questionable CGM readings.
Accuracy, current use, and sources
A UK national clinical consensus advises that CGM does not replace home blood-glucose testing and that missed hypoglycemia remains possible. After stabilization in the hospital, many children have meter checks every two to four hours before feeds, but the appropriate home schedule depends on the child’s glucose stability, feeding plan, medicines, and current circumstances.
In a small study involving ten people with hyperinsulinism, the Dexcom G7 detected about 62% of low-glucose episodes. That was better than the earlier G6 device, but it meant that the G7 still missed nearly four in ten lows in that study. Families have also reported benefits from seeing glucose patterns alongside burdens such as false alarms, confirmation checks, sensor failures, and troubleshooting. CGMs are increasingly used in CHI, but they are not approved specifically for CHI in the United States and their use in infants should be guided by a specialist team.
What it adds: Keeping glucose safe is the first priority, and follow-up also checks how a child is developing and feeding. International guidelines recommend developmental follow-up and feeding assessment for all children with HI, even when no difficulty is immediately apparent.
What care can involve: Age-appropriate developmental testing and, when useful, early help from feeding, physical, occupational, speech-language, or neurodevelopmental specialists. A referral does not mean that a problem is expected. It gives families a way to identify and address concerns early.
Why follow-up matters and sources
Developmental and feeding difficulties have been reported in children with both transient and persistent HI. The type and timing of follow-up are individualized according to the child’s history, development, and current needs.
02 · How CHI can change over timeTreatment needs may lessen or resolve, continue into adulthood, or change in other ways over time.
CHI does not follow one path. Some people need less treatment as they grow, while others continue to have hypoglycemia or later develop a different glucose-control problem. These differences reflect the biology of CHI, not how hard a family has tried.
Reduced treatment needs or remission
Some people need less treatment over time
Medicine, added carbohydrate, or feeding support may sometimes be reduced or stopped after a CHI specialist confirms that glucose remains safe. Researchers may call this clinical resolution or remission of hypoglycemia. When hypoglycemia resolves as part of CHI’s course, rather than because pancreatic surgery produced the improvement, researchers may call it Resolution of hypoglycemia during CHI’s course, rather than as the result of pancreatic surgery. The improvement may be gradual.. It may develop gradually over months or years; “spontaneous” does not mean instantly. Remission also does not mean that a genetic variant has disappeared.
Spontaneous remission has been documented in both focal and diffuse KATP-channel CHI. Small selected studies report encouraging results, including remission in 12 of 17 nonsurgical patients in a Spanish ABCC8 cohort. Researchers still cannot give families a reliable remission percentage for either form. Focal lesions are usually removed, while studies that follow diffuse CHI without surgery include patients whose clinical teams had chosen continued medical management.
What the studies can tell us, how specialists assess remission, and sources
In a selected UK cohort of 21 medically managed people with KATP-channel CHI, hypoglycemia resolved in both confirmed focal cases and in 13 of 19 diffuse or presumed-diffuse cases. A recent French focal-CHI study documented four selected children who avoided surgery and were free of hypoglycemia before age six, but most participants underwent surgery, so it cannot provide an overall spontaneous-remission rate for focal CHI.
A Danish study followed a selected group with persistent non-focal CHI to a median age of 5.3 years. Only three of the 23 conservatively treated patients had entered remission by their last recorded follow-up, but those three did so relatively late, between ages 11.4 and 16.6. The authors noted that additional patients might enter remission with longer follow-up.
Fewer noticeable symptoms alone do not establish remission. A specialist may review glucose records and use a supervised safety fast or another individualized assessment before reducing treatment.
Some forms remain active after childhood, sometimes with symptoms that are less obvious than they were in infancy. In one study of dominantly inherited KATP-channel CHI, 15 of 29 adults reported continuing symptoms of hypoglycemia, in some cases through age 68; two still used diazoxide. This group does not represent every form of CHI, but it shows that remission is not universal.
Young people who continue to need CHI care can benefit from a planned transition from pediatric to adult endocrine care, with a clear summary of their diagnosis, earlier treatment, and current plan.
Study context and sources
The adult study involved mostly milder, dominantly inherited KATP-channel CHI. Its findings should not be used to estimate how often other forms continue into adulthood.
For some people with ABCC8-related CHI, the pancreas may later release too little insulin and glucose levels may rise. In the small study described above, 5 of the 12 people who entered remission later developed diabetes with insufficient insulin secretion. Their tests did not show the usual autoimmune pattern of type 1 diabetes. The study was small and selected, so its percentage cannot predict one person’s risk.
If diabetes develops: Treatment depends on how much insulin the pancreas still makes. Continuous glucose monitors can help track glucose patterns, and people who need insulin may be able to use pumps or automated insulin-delivery systems. These tools still require attention, but they can make glucose management more precise and manageable than it was in the past.
After pancreatic surgery: Removing a focal lesion can cure focal CHI. Extensive surgery for diffuse CHI creates a different long-term path: hypoglycemia may continue at first, while diabetes or pancreatic enzyme insufficiency can develop later.
Long-term evidence and sources
Periodic follow-up can help a care team look for either recurring low glucose or a later rise in glucose. The type and frequency of follow-up depend on the person’s form of CHI, treatment history, and current health.
03 · Potential future treatments studied in people with CHIApproaches that have reached human studies. The summaries explain what researchers found and where each program stands.
Under FDA review · Not approved for CHI
Dasiglucagon
Why it might help: Glucagon raises glucose by telling the liver to release stored glucose and make additional glucose. Standard rescue glucagon is difficult to keep dissolved for prolonged pump use. Dasiglucagon is a more stable form designed for continuous delivery through a wearable pump.
Which children might benefit: In the hospital, it could reduce the amount of intravenous glucose needed by infants with severe CHI and potentially help them move away from intravenous treatment. At home, researchers have studied whether it could reduce hypoglycemia or dependence on intensive feeding support.
What studies found: A hospitalized-infant study found that dasiglucagon reduced intravenous glucose requirements. A separate home-use study did not meet its planned main outcome, although later exploratory CGM analyses were more encouraging.
What it could change day to day: A stable glucagon pump could provide another option for children whose CHI is not adequately controlled by medicines that reduce insulin release. It would still require an infusion site, pump supplies, monitoring, and plans for pump interruptions.
Current status, limitations, and sources
As of August 24, 2026, the sponsor described a U.S. application covering treatment for up to three weeks as under FDA review, with longer-duration use handled separately. Regulatory review is not approval.
Why it might help: Efpegerglucagon is a long-acting form of glucagon intended to help the liver maintain glucose despite continued excess insulin. Unlike dasiglucagon, which is designed for continuous pump delivery, efpegerglucagon is being studied as a once-weekly injection added to existing CHI care.
Which children were studied: The Phase 2 study enrolled people age two and older who continued to have hypoglycemia despite stable medicines and nutritional support.
What early results suggest: Interim results reported fewer hypoglycemia and severe-hypoglycemia episodes during eight weeks of treatment, with generally favorable short-term tolerability. The study is small, and complete peer-reviewed results are still needed.
What it could change day to day: If later studies confirm the findings, a weekly injection might reduce hypoglycemia or some feeding and treatment burden without requiring a continuous pump. It would not directly correct abnormal insulin release.
Study details and sources
The Phase 2 study is active but is no longer recruiting. In February 2026, the FDA granted efpegerglucagon Breakthrough Therapy designation for CHI. That designation can speed development and review, but it is not approval. The available efficacy findings come from sponsor and meeting reports rather than a completed peer-reviewed paper.
What it is: An antibody designed to reduce how strongly excess insulin acts on the body. It does not directly stop beta cells from releasing insulin. Instead, it attaches to Proteins on the surface of many cells that receive insulin’s signal. When insulin activates these receptors, cells and organs change how they use, store, or release glucose. and partially turns down their response to insulin.
What studies found: An open-label Phase 2 study reported improvement from baseline. In the later randomized Phase 3 study, the planned statistical comparisons did not show a reliable advantage for ersodetug on either the main measure or the most important secondary measure. This does not mean that no participant improved. It means that the trial did not demonstrate a group-level advantage on those measures.
What it could change day to day: An intermittently given medicine might reduce some daily treatment tasks, but injections, monitoring, visits, allergic-reaction risk, and long-term follow-up would still matter.
Current status, limitations, and sources
After a March 2026 meeting, the sponsor said FDA requested complete study reports and analysis datasets before possible next steps are determined. No approval for CHI was identified as of August 24, 2026.
What it is: GLP-1 is a hormone signal released by the gut after eating. It can help beta cells release insulin. Avexitide blocks the receptor that receives this signal, which may weaken one of the signals promoting inappropriate insulin release in CHI.
What studies found: In small, short controlled studies involving people with KATP-channel CHI, the research medicine raised glucose during fasting and food challenges and reduced the likelihood of hypoglycemia. These studies tested brief infusions rather than long-term treatment at home. Larger and longer studies would be needed to understand its effectiveness, dosing, and everyday use.
Current status and sources
GLP-1 stands for glucagon-like peptide-1. The research medicine was originally called exendin-(9-39) and is now known as avexitide. The sponsor says it is discussing next steps for CHI. A separate Phase 3 program concerns post-bariatric hypoglycemia, not CHI.
Promising, very early human evidence · Three reported patients
Alpelisib
What it is: An oral medicine that blocks a signaling protein called PI3K alpha, which is part of the pathway through which insulin affects cells. It is approved for certain cancers and PIK3CA-related overgrowth syndrome, but not for CHI.
Why researchers are interested: In reports published in 2024 and 2025, three children with severe genetic CHI improved within weeks to months after starting alpelisib. The first child no longer required continuous intravenous glucose and avoided a planned near-total pancreatectomy. The two children reported in 2025 discontinued their existing CHI medications and moved to much less restrictive feeding schedules. One progressed from G-tube feedings every two hours to every five hours. The other stopped continuous overnight feeding and began feeding on demand, despite having persistent CHI after an earlier near-total pancreatectomy.
Why it may matter: These results make alpelisib a promising potential treatment for some children with severe diffuse KATP-channel CHI whose glucose cannot be controlled adequately with established treatments. Unlike medicines that reduce insulin release, alpelisib reduces the effects of insulin on the body.
Major limitations, safety context, and sources
These cases were reported in 2024 and 2025 by a specialist team at Sidra Medicine in Doha, Qatar. One of the later cases also involved collaboration with a hospital in Kuwait.
So far, alpelisib has been reported in only three children, without a controlled clinical trial and with follow-up measured in months. Mild hyperglycemia required a dose adjustment in one child. In its approved uses, alpelisib can cause hyperglycemia, rash, diarrhea, mouth sores, and, rarely, diabetic ketoacidosis. Its long-term safety and effectiveness for children with CHI are unknown.
04 · Earlier-stage research in CHI cells, tissues, or animalsStudies that help researchers understand CHI and decide which ideas are worth developing further.
CHI research can use cells, pancreatic tissue or islets, and animal models. Each can answer different questions.
Cells
Engineered cells and patient-derived stem-cell models can show how a variant changes channel movement or insulin release.
Tissues and islets
Isolated pancreatic islets or tissue can reveal behavior that a single cell type may not capture.
Animals
Researchers use mice with altered Abcc8/Sur1 or Kcnj11/Kir6.2 channels. These mice do not reproduce every feature of human CHI.
Tested in CHI-related cells
Aekatperone and pharmacochaperones
Some ABCC8 variants make SUR1 proteins that do not reach the beta-cell surface correctly. A pharmacochaperone is a small molecule that may help a poorly trafficked protein reach the right place.
In cells, aekatperone helped certain mutant KATP channels reach the surface and recover function after the compound was removed. Responses differed by variant.
What researchers would study next: Animal studies could explore whether the approach works safely in a whole pancreas. This strategy would apply only to variants with a rescueable trafficking problem.
Study details and sources
The work combined computational screening, laboratory testing, and cryo-electron microscopy to develop a variant-specific treatment concept.
CRISPR is a gene-editing tool that researchers can use in laboratory-grown cells. In one study, researchers reprogrammed cells from a person with ABCC8-related CHI into stem cells and grew them into clusters containing beta-like cells. They corrected the ABCC8 mutation in a matched set of cells and compared the corrected and uncorrected cells. Another research team used CRISPR to create cells without working ABCC8.
What researchers learned: The uncorrected beta-like cells released excessive insulin when glucose was low, while the corrected cells regulated insulin more normally. Comparing otherwise closely matched cells helps show which effects are caused by the mutation.
Why this matters: These models let researchers study CHI and test possible treatments without requiring pancreatic tissue from a child. They do not show that CRISPR can yet be delivered safely to enough beta cells in a person.
05 · Longer-term research conceptsIdeas that might eventually contribute to CHI care if researchers can solve major scientific and delivery challenges.
Longer-term research concept
Gene editing
Some forms of CHI are caused by a mutation in ABCC8, KCNJ11, or another gene. In some cases, the mutation is a change in a single DNA letter. In theory, gene editing could correct certain mutations inside affected beta cells, allowing the cells to make working proteins and regulate insulin more normally. Base editing can replace certain individual DNA letters. Prime editing can make a wider range of small corrections. Neither approach has been tested as a treatment for CHI.
What researchers would need to solve: The editing treatment would have to match the person’s particular mutation and reach enough affected beta cells. Researchers would also need to avoid unintended DNA changes and other tissues, limit immune reactions, make the correction last, and ensure that the corrected cells continue releasing an appropriate amount of insulin.
Additional gene-editing sources
A patient-specific liver-targeted editing treatment in another rare disease provides another example of editing inside the body. Reaching pancreatic beta cells remains a separate research challenge.
Another possible approach for some forms of ABCC8-related CHI in which neither copy of the gene works normally would be to give affected beta cells working ABCC8 instructions rather than repair the original gene. One commonly studied carrier is an AAV stands for adeno-associated virus. Scientists can modify this very small virus so that it carries selected genetic instructions into cells and cannot reproduce on its own. In this context, the modified virus is being studied as a delivery vehicle, not as a treatment for an infection..
The ABCC8 instructions almost fill the amount of DNA that one AAV vector can carry, even before adding the additional DNA needed to control which cells use the instructions and how much protein they make. Researchers might therefore have to divide the ABCC8 instructions between two AAV vectors. Both parts would need to enter the same beta cell and join correctly. This approach has not been tested for CHI.
What researchers would need to solve: The delivery vehicles would need to reach enough affected beta cells. The two parts would have to join reliably and direct each cell to make the right amount of SUR1. SUR1 would then need to join with the channel’s other part, Kir6.2, to form working KATP channels. Researchers would also need to limit immune reactions and determine whether treatment could be repeated.
Platform evidence and sources
Researchers have developed small DNA switches intended to turn delivered genes on mainly in beta cells. Separate studies have shown that genetic instructions divided between two AAV vectors can be joined in other cells and tissues. Neither study tested an ABCC8 treatment for CHI.
Instead of adding or permanently editing DNA, a future CHI treatment might deliver mRNA that temporarily tells beta cells to make a working protein. For example, in some forms of ABCC8-related CHI in which beta cells do not make enough working SUR1, mRNA might provide instructions for making it. Because mRNA breaks down naturally, the effect would fade and treatment would probably need to be repeated.
Experimental Tiny fat-based particles that protect mRNA and help carry it into cells. Their chemical design affects which tissues and cells they reach. have delivered mRNA to pancreatic beta cells in mice and caused those cells to make a test protein. Researchers have not yet used this approach to deliver ABCC8 instructions or treat CHI.
What researchers would need to solve: The particles would need to reach enough affected beta cells while avoiding other tissues, carry CHI-relevant mRNA, produce the appropriate amount of protein, and remain safe with repeated treatment.
Which form of CHI does the team think this is, and what supports that conclusion?
What is each treatment intended to change: insulin release, insulin action, glucose supply, or fasting tolerance?
How will the team decide whether the treatment is working?
What monitoring and side effects should we understand?
How could this plan fit into the family’s daily and overnight routines?
How might recent studies of medically managed ABCC8-related CHI, including this long-term Spanish study, apply to my child’s genetic findings, pancreatic form, disease severity, and current glucose control?
If near-total pancreatectomy is being considered for diffuse CHI, what is the goal for this child, and what outcomes has this center seen in similar cases?
Before deciding whether to proceed with near-total pancreatectomy for diffuse CHI, families can seek an independent second opinion from another specialist CHI center of their choice, ideally one experienced in evaluating both surgical and nonsurgical approaches.